Does excluding subjects with features similar to IPF affect the results of the INBUILD trial of nintedanib?
L. Richeldi (Rome, Italy), A. Wells (London, United Kingdom), V. Cottin (Lyon, France), B. Crestani (Paris, France), M. Molina Molina (Barcelona, Spain), R. Goeldner (Biberach, Germany), S. Stowasser (Ingelheim am Rhein, Germany), R. Schlenker-Herceg (Ridgefield, CT, United States of America), Y. Inoue (Sakai City, Osaka, Japan)
Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Richeldi (Rome, Italy), A. Wells (London, United Kingdom), V. Cottin (Lyon, France), B. Crestani (Paris, France), M. Molina Molina (Barcelona, Spain), R. Goeldner (Biberach, Germany), S. Stowasser (Ingelheim am Rhein, Germany), R. Schlenker-Herceg (Ridgefield, CT, United States of America), Y. Inoue (Sakai City, Osaka, Japan). Does excluding subjects with features similar to IPF affect the results of the INBUILD trial of nintedanib?. 740
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: